Annual revenue was KRW 8.41 billion in 2022, the largest year in the 2022–2025 period, and KRW 374 million in 2024, the smallest. Revenue fell 87.8% to KRW 1.03 billion in 2023 and then dropped a further 63.7% to KRW 374 million in 2024. It recovered to KRW 2.46 billion in 2025, up 557.3% from the prior year.
The company attributed the 2025 revenue increase to expansion of its global vaccine and CDMO businesses, and the narrower loss to cost reductions from bioplant operating efficiencies. The operating loss was KRW 22.4 billion in 2022, KRW 16.9 billion in 2023, KRW 19.7 billion in 2024 and KRW 10.3 billion in 2025.
The loss widened again in 2024, so the trend has not been a straight line. Operating margin was -266.4% in 2022, -1,643.8% in 2023, -5,275.4% in 2024 and -420.6% in 2025. When revenue is this small, percentage margins swing sharply, so absolute loss amounts are the more useful gauge.
Net loss attributable to controlling shareholders was KRW 36.3 billion in 2022, KRW 17 billion in 2023, KRW 26.3 billion in 2024 and KRW 29.7 billion in 2025. In 2025 the operating loss narrowed from 2024, yet the controlling-shareholder net loss widened to KRW 29.7 billion.
In the fourth quarter of 2025 the controlling-shareholder net loss reached KRW 12.3 billion against an operating loss of KRW 2.17 billion, a gap of more than KRW 10 billion that points to large non-operating items.
Quarterly revenue was KRW 9.47 million in the first quarter of 2026, KRW 320 million in the second and KRW 220 million in the third, a wide swing. The operating loss of KRW 3.01 billion in the second quarter of 2026 was the largest of the last five quarters, easing to KRW 2.92 billion in the third.
Total equity was KRW 44.3 billion at the end of 2025, and the debt ratio fell from 127.8% in 2024 to 23.7% in 2025.